CONNECTING IMAGING TO CARE

EOS imagingCorporate PresentationMike Lobinsky, CEO

Valérie Worrall, CFO

October 14, 2019

> This document has been prepared by EOS imaging (the "Company") and is provided for information purposes only.

> The information and opinions contained in this document speak only as of the date of this document and may be updated, supplemented, revised, verified or amended, andsuch information may be subject to significant changes. EOS imaging is not under any obligation to update the information contained herein and any opinion expressed in thisdocument is subject to change without prior notice.

> The information contained in this document has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to the accuracy,completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiary, its advisors and representatives accept noresponsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

> This document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawnfrom various sources or from the Company’s own estimates. Investors should not base their investment decision on this information.

> This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward looking statementsrelate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yetdeterminable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or maynot materialize in the future. EOS imaging draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of theCompany's future performance and that the Company’s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operate maydiffer materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if EOS imaging’ financial position, results,cashflows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results ordevelopments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or toconfirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occurafter the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of EOS imaging, or on itsability to meet its targets, appears in the "Risk Factors" section of EOS imaging Registration Document registered with the Autorité des marches financiers

> Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables are therefore notnecessarily equal to the sum of the individually rounded figures, amounts or percentages.

> This document does not constitute or form part of an offer to sell or to purchase securities or the solicitation of an offer to purchase securities in the United States of America orin any other jurisdiction. The securities mentioned in this presentation have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the“Securities Act”) or under any other legislation of any jurisdiction in the United States of America and may not be offered or sold in the United States absent registration or anapplicable exemption from registration under the Securities Act.

Disclaimer

EOS imaging: EOSI.PA

3

Connecting Imaging to Care

~170 employees, including an R&D team of 45 engineers

Clearance to market in 51 countries incl. U.S. (FDA), Japan, China, and the European Union (CE), with >300 units installed worldwide

Unique, innovative, low dose 2D/3D full body imaging and software solutions bridging the gap between imaging and orthopedic surgery

Targeting a ~€2 billion per year addressable market

Direct commercial presence and tactical partnerships with offices in Paris France (HQ), Cambridge Massachusetts, Montreal Quebec, Besançon France, Frankfurt Germany, and Singapore

Created from a technology developed by Dr Georges Charpak, awarded Nobel Prize in Physics, with growing medical endorsements, including >385 publications since 2012

4

Company Milestones

Continued Innovation and Growth

1992

1998

2007

2008

2012

2014

2017

2018

2019

Radiation detection technology used to create EOS imaging was awarded the Nobel Prize in Physics

Initial steps in medical radiology under Marie Meynadier’s leadership

EOS® receives CE mark, initial commercialization team established

FDA clearance received. First EOS systems installed in Europe and North America

EOS imaging listed on Euronext Paris (EOSI)

EOS imaging installs 100th

system globally and authorized to market in 48 countries

Receives FDA clearance on EOSapps surgical planning portfolio and launches EOS 3Dservices

100 EOS systems installed in U.S. and 300 systems globally. EOS Private Practice Program launched in U.S.

Mike Lobinsky transitions into CEO role

5

Management Team

Combined 140+ Years Medical Technology Experience

Mike Lobinsky – Chief Executive Officer

• 20+ years medical device experience including senior management positions at Smith and Nephew, Brainlab, Blue Belt Technologies, Stryker Corp

• Joined EOS imaging in 2017• Appointed CEO January 2019

Valerie Worrall - Chief Financial Officer

• 20+ years finance experience in the healthcare industry including Novartis and previously CFO of Balt

• Joined EOS imaging in 2018

Eric Maulave - Chief Operating Officer

• 25+ years experience including business engineer for the IT and multimedia sectors and international Sales and Marketing Director within the Philips Group

• Joined EOS imaging in 2012

Didier Saint-Felix - Transformation Director

• 30+ years experience in the research and development of innovative medical imaging systems.

• Began his career at the French National Center for Scientific Research (CNRS) and then led R&D at General Electric Healthcare

• Joined EOS imaging in 2006

Kären Solie - Vice President Global Marketing

• 25+ years marketing experience in the medical device industry including senior marketing and market development positions at Stryker, Mako Surgical, superDimension, Covidien (Medtronic), Smith & Nephew and AxoGen

• Joined EOS imaging in 2018

Maurice Delplanque- Vice President of Engineering

• 20+ years experience in R&D and engineering in the healthcare industry

• Contributed to the development of the first digital radiography of neurology and cardiovascular systems at General Electric Healthcare

• Joined EOS imaging in 2007

7

EOS – Recognized 2D/3D Low Dose Radiology Solution for Orthopedics

Basic offering

Imaging

EOS systemBiplanar, low dose image capture

Imaging center takes full-body images of patients in a standing or seated position

sterEOS workstation3D modelling done by radiology technicians

1st generation visualization of 3D

Manual 3D modeling

8

One of the 5 imaging modalities

CT Scan

MRI

Conventional radiography

Ultrasound

EOS System

9

Differentiated Orthopedic Imaging Platform

Addressing Weaknesses in Conventional Imaging

1Patients treated for Adolescent Idiopathic Scoliosis had an overall cancer rate 5 times higher than of an age matched populationIncidence of cancer in adolescent idiopathic scoliosis patients treated 25 years previously, Simony A et al. Eur Spine J. 2016

EOS Platform X-ray: CR/DR CT Scanner MRI Ultrasound

Low dose1P P P

3D imaging P P* P*

Full-body(no stitching) P P P

Weight-bearing P P P

Low cost P P

*Only available in non functional positions

EOS X-Ray

Continuous, full-body imaging

Imprecise, stitched imaging

Bone imaging Soft tissue imaging

Other orthopedic imaging modalitiesExam

time cut up to

80% vs Xray

Dose cut2-10x

vs Xray

10

EOS Orthopedic Solutions

Expansion Beyond Radiology System & Creation of Two Focused Divisions In 2019

Advanced Orthopedic Solutions Division Imaging Division

11

EOSapps Gaining Traction in Orthopedic Surgery Planning

Web-based, 3D Planning & Simulations of Surgical Outcome

spineEOS› Open architecture (currently) – able to add

vendor specific CAD screws, cages, rods, other

› 3D rod information exportable to rod bender or 3D printer

hipEOS› 3D range of motion simulations of surgical

outcome based on pre-op plan› Better understand patient’s hip & spine

relationship and identify patients at risk of early revision/dislocation

kneeEOS› Real time optimization of knee alignment and surgical

strategy› Automatic proposal of implant size and position according

to EOS images and 2D/3D patient dataset› Open platform, enables compatibility with all primary TKA

implants

Provides for inventory management and optimal instrument set logistics

12

Launch of EOSlink™

Integration of EOS images + 3D models + EOSapps surgical plans into the operating room

Patient specific 3D planning and transfer of EOSapps data in the OR

Seamless integration with existing intra-operative execution systems, including navigation and robotics-based platforms

Secure data transfer

13

~€2b Addressable Market Opportunity

1More than 100 joint orthopedic and/or 30 complex spine surgeries per year, worldwide estimation2Considering: services charged at €200 per surgery with 200 surgeries per EOS platform per year & 1 platform per site

€0,7b €0.5b €0.5b

Equipment +

• €400k ASP• Renewal market for

7-year lifetime• 12,000 sites with

significant orthopedic surgery volumes1

• €45k per unit • Online services and consumables2 (patient specific instruments)

€1.7b

Total

€0.7b

Maintenance Services =

15

Installed Base Growth by Region

300 units Worldwide

16

Over 330 Systems Installed Worldwide

EMEA45.1%NAM

38.6%

Asia-Pac.16%

Lat. Am0.3%

(1)

EOS Installed Base

17

Global Sales Channels

Addressable Market Represents ~12,000 EOS® Systems Worldwide

Co-marketing program

Partnership associating EOS equipment to implant volumes in multi-year implant procurement contracts

Direct Sales Distributors & Agents Strategic Partnerships

18

› Privately owned orthopedic practices operate their own imaging equipment

› >10 private practices purchased EOS

Continued Expansion Beyond Hospital Market

Growing Adoption in Imaging Centers & Orthopedic Private Practices

France: >80 EOS Installed 70% In Private Imaging Centers

› 2/3 of radiologists are in private sector

› Serving orthopedic surgery private clinics

Australia: 20 EOS Installed70% In Private Imaging Centers

Germany: 13 EOS Installed 40% In Private Settings

› Serving orthopedic private clinics

U.S.: >110 EOS InstalledLaunched Orthopedic Private Practice Program

› Serving orthopedic surgery hospitals and private clinics

19

U.S. Market Opportunity

~2% Penetration Rate

~ 1,000 tier one hospitals

~ 5,000 hospitals

(w/ inpatient treatment)

~100+ installed

Private Ortho Groups Practice

~ 750 tier one Practices

~ 1,600 private practices

(w/o inpatient treatment)

10+ installed

20

EOSone Program Traction

Opening up new segment with EOSone in the U.S.

Launch of EOSone Private Practice Program in US with greater focus on customer targeting and financing options to minimize capital outlay

Example at Cantor Spine Institute, the first private practice in Florida to install the EOS system with EOSone program

60%+ growth in EOSone Opportunity Growth in 2019

21

Continued US Top Hospital Penetration

Group Purchasing Contracts with Major Hospital Networks

22

Top U.S. Hospital Penetration

Leveraging Customer Networks to Accelerate Expansion

Increased Usage Driving Repeat Purchases

Hospital for Special Surgery (HSS)#1 orthopedic hospital in US

(US News & World Report 2019-2020)

Advocate Good Samaritan Hospital333-bed community hospital in US (Illinois)

Bone & Joint Center - HMCBranch of Hamad General Hospital - QATAR

✓ 41% Average increase in EOS exams ordered annually since year 1

✓ 125 Total number of physicians ordering EOS exams

✓ 4X Number of EOS systems installed in HSS network

✓ 1,461 Total number of EOS exams performed year 1

✓ 76% Percentage of full body exams✓ 2X Number of EOS systems installed

in Advocate Healthcare network

✓ 161%+ Percent of EOS exam growth year 1 to year 2

✓ ≈70% Percentage of full body exams✓ ≈20% Percentage of lower limb

exams

24

Global Top Hospital Penetration

EOS in 7 of the top 10 best hospitals in the world

1. Mayo Clinic

2. Cleveland Clinic*

3. Singapore General Hospital (Bukit Merah)

4. The Johns Hopkins Hospital (Baltimore)

5. Charité (Berlin)

6. Massachusetts General Hospital (Boston)

7. Toronto General Hospital

8. University of Tokyo Hospital

9. Lausanne (Switzerland) University Hospital

10. Sheba Medical Center (Tel Aviv, Israel)

TOP # 10

WORLD BEST HOSPITAL

*https://www.newsweek.com/2019/04/05/10-best-hospitals-world-1368512.html

25

› Expanding alliance with a leader in the industry

› 10th EOS installation within the group at GRH Le Havre

› Total opportunity of 40 centers in the group

EOS System France Network Expansion

Partnership agreement with VIDI Group : 10th installation in the group

Reimbursement opening up in Germany

Enhanced reimbursement for spine and lower limb exams

✓ Reimbursement coverage for EOS exams approved in Germany in August 2019.

✓ The reimbursement for public patients has now been approved by the local authorities (KBV) for both Spine and Lower Limb exams.

✓ Important step towards EOS imaging’s ability to develop in the German medical imaging market.

27

Continued Growing Medical Endorsement and Publications

Increasing Global Visibility

› Growing number of publications and podium presentations on EOS

› Meet The Experts: Surgeon presentations at EOS’ booth during major shows

› EOS Webinar Series: Symposiums with KOL presenters re-aired

28

U.S. Spine KOL Team

Defining the future of spine treatment

Dr. ShaffreyChief of Spine DivisionDuke Health - Durham, NC• 2011-2018 Best Doctors in America® List• 300+ publications, greater than 750 national and

international presentations and served as editor for several textbooks on spinal surgery

• Chair of IMAST, member of ISSG

Dr. BessOrthopaedic Surgeon Denver International Spine Center (DISC) - Denver, Colorado• Member of the SRS, NASS, current Chair of ISSG

Dr. NewtonChief of the division of Orthopedics & Scoliosis,Rady Children’s Hospital - San Diego, CA• One if not the most respected pediatric spine

surgeons worldwide• Over 250 publications, 5500 citations• Numerous chairs, current president of the SRS, head

of HSG

Dr. BucklandAssistant Professor, Department of Orthopaedic Surgery,NYU Langone - New York, NY

Dr. HeyFounder & Surgeon Hey Clinic for Scoliosis and Spine Surgery - Raleigh, NC

Dr. LenkeSurgeon-in-Chief at The Spine HospitalNew York Presbyterian - New York, NY• One if not the most respected spine surgeon

worldwide• Over 450 publications and 1000 presentations• Defined the classification of scoliosis used worldwide

(Lenke Clasification) • Former chair of the SRS and key member of the ISSG

Dr. ParentAssociate Professor, Department of SurgeryCHU St. Justine - Montreal, Canada• Member of the SRS, NASS, current Chair of ISSG

29

THA/TKA KOL’s

Defining the future of joint replacement

Dr. VigdorchikTHA-TKA surgeon at HSS, formerly at NYU• Strong research focus on hip-spine relationship• Over 87 publications

Dr. MaymanTHA-TKA surgeon at HSS• High interest in technology • Strong research focus on accurate placement of

acetabular cup and hip-spine relationship• Over 94 publications

Dr. SculcoTHA-TKA surgeon at HSS• Strong research focus on hip-spine relationship• Over 129 publications

Dr. LazennecSpine and hip surgeon at La Pitié Salpétrière hospital (France)• Known as a pioneer in the assessment of spine-hip relationship in THA• First publication on this topic years ago • Over 132 publications to date

30

Q3 Highlights

Visible Presence at Major Scientific Society Meetings

› Successful Scoliosis Research Society (SRS) 54th Annual Meeting :

• EOS images and 3D models supported more than 35 podium presentations and scientific posters

• Highlights the importance of EOS in the management of scoliosis, assessment of sagittal alignment and surgical planning

› North American Spine Society (NASS) 34th Annual Meeting with :

• A prototype of a new Auto 3D modeling application, which uses artificial intelligence to automatically generate weight-bearing 3D spine models showcased at the congress

• Auto 3D very well received by attendees

CONNECTING IMAGING TO CARE

2019 9-Month Revenue

32

EOS imaging | 9-month Revenue 2019 Key Facts

Highlights

2019 YTD

Equipment Orders of

44 units

€5.8m recorded in Q3 2019, i.e. +5.9%

versus Q3 2018

€18.6mEquipment

orders

€26.6m commercial

performance as of

September 2019

led by EMEA (+24%) and NAM (+13%)

offset by a high H1 2018 comparable base

in APAC and LATAM

+4%Commercial Performance

+4% increase in

ASP over 2019 YTD,

excl. LATAM

primarily driven by North America

+4%ASP

growth

11 EOS Systems

delivered since

January 2019

9 Equipment delivered in Q3

marking the gradual and expected

restart of billing

€4.3m Equipment

sales

€8.0m of recurring revenues

+25% in recurring

revenues recorded

since January 2019

driven by maintenance

contracts revenue

*(equipment orders + recurring revenues)

Change in Commercial Cycle in 2019

33

Better meet customer satisfaction and reduce working capital

In order to better meet customer expectations and improve its working capital, EOS imaging made a

change in its commercial cycle at the beginning of 2019 by organizing the delivery of EOS® systems at the

start of the installation phase, and no longer at the receipt of the equipment order. This evolution has

created a transition period during which (i) new received orders build an order book and (ii) sales are

recorded according to the pace of delivery of the EOS® systems. As installations usually take place 3 to 12

months after the order, a similar lag is expected on deliveries. While 2019 revenues are temporarily

impacted by the transition phase, this evolution leads to improvements in production and logistics

management, and contribute to the reduction of working capital.

34

EOS imaging | Q3 & 9-months 2019 Equipment Orders –

Solid business performance with 44 EOS® system orders booked as of September 2019

EOS imaging 3rd Quarter Equipment Orders by RegionEUR million

EOS imaging 9-months Equipment Orders by RegionEUR million

› €18.6 million of equipment orders booked over 9-months 2019, i.e. -2.4% vs 2018 due to high comparison base in APAC over H1 2019 not yet offsetdespite the strong momentum in the region over Q3 2019 (+61.0%), and to one spot sales in LATAM in Q3 2018

› €5.8 million of equipment orders booked in Q3, +5.9% vs 2018 driven by EMEA (+91.9%). Q3 order rhythm in NAM impacted by the strong order booking in Q2 2019 (+52%).

4.9 5.3

8.2

0.7

19.1

6.3

3.6

8.7

-

18.6

EMEA APAC NAM LATAM GLOBAL

2018 9-months 2019 months

+29.3% -32.3% +6.5% -2.4%

0.8 1.1

2.9

0.7

5.5

1.6 1.82.4

-

5.8

EMEA APAC NAM LATAM GLOBAL

2018 Q3 2019 Q3

+91.9% +61.0% -14.3% +5.9%-100% -100%

35

EOS imaging | Order Book as of September 30, 2019

Gradual build-up of Order Book since January 2019

› €14.4 million Order Book as of September 30, 2019 resulting from Equipment orders (€18.6m) less 9-months sales (€4.3m)

EOS imaging Order Book VariationEUR million

€6.3m#15 EOS©

€-0.1m €6.2m

€-0.7m#2 EOS©delivered

€12.1m

€-3.5m#9 EOS©delivered

€14.4m

Quarterly Equipment new Orders Quarterly Revenues recorded from Equipment delivered

€6.6m#15 EOS©

€5.8m#14 EOS©

Equipment Oder Book Value as of end of the quarter

36

6.48.0

19.1

4.3

14.4

2018 9-months 2019 months

Recurring Revenues Equipement Sales Order Book Variance

2.5 2.8

5.53.5

2.3

2018 Q3 2019 Q3

Recurring Revenues Equipement Sales Order Book Variance

EOS imaging | Q3 & 9-months 2019 Commercial Performance

Progressive restart of sales invoicing of EOS© systems after change in commercial cycle effected in January 2019

EOS imaging 3rd Quarter Commercial PerformanceEUR million

€8.0m€8.6m

EOS imaging 9-months Commercial PerformanceEUR million

€25.5m€26.6m

Recurring Revenues Performance Equipment Orders

› €12.3 million of revenues generated over 9-months 2019

› €4.3 million of equipment sales, of which €3.5 millions recorded over Q3 2019

€12.3m9-monthsrevenues

€6.3mQ3 revenues

37

Revenues fueled by the recording of 11 EOS® systems and recurring revenues

Revenues by product linesNon-audited / Including forex impact / € million / As of September 30

9-months

2019

9-months

2018

Equipment 4.28 19.10

Maintenance contracts 7.16 5.76

Consumables and services 0.83 0.65

TOTAL REVENUES 12.27 25.51

Revenues by geographiesNon-audited / Including forex impact / € million / As of September 30

9-months

2019

9-months

2018

EMEA 6.60 8.19

APAC 1.29 5.75

NAM 4.39 10.86

LATAM - 0.71

TOTAL REVENUES 12.27 25.51

› €12.3 million of revenues generated over 9-months 2019, of which

› €4.3 million of equipment sales, included €3.5m recorded in Q3 2019, and €8.0m of recurring revenues (i.e. +24.7% vs. 2018)

EOS imaging Quarterly Revenues Evolution over 2019 YTDEUR million

2.5 2.7 2.8

0.1

0.7

3.5

2019 Q1 2019 Q2 2019 Q3

Recurring Revenues Equipement Sales

› Gradual restart of sales invoicing of EOS© systems

EOS imaging | 9-months 2019 Detailed Revenues Breakdown

€2.6m

€3.4m

€6.3m

38

14 EOS® system orders and 9 equipment sold over Q3 2019

Revenues by product linesNon-audited / Including forex impact / € million / As of September 30

Q3

2019

Q3

2018

Equipment 3.51 5.50

Maintenance contracts 2.50 2.30

Consumables and services 0.26 0.17

TOTAL REVENUES 6.27 7.97

› €6.3 million of revenues generated over Q3 2019, down by -21.3% compared to the third quarter of 2018

› €3.7 million recorded in EMEA, close to normalized level due to the shorter commercial cycle in the area

EOS imaging | Q3 2019 Detailed Revenues Breakdown

Revenues by geographiesNon-audited / Including forex impact / € million / As of September 30

Q3

2019

Q3

2018

EMEA 3.68 1.91

APAC 0.93 1.31

NAM 1.65 4.03

LATAM - 0.71

TOTAL REVENUES 6.27 7.97

EOS imaging Quarterly Revenues Evolution over 2019 YTDEUR million

2.5 2.7 2.8

0.1

0.7

3.5

2019 Q1 2019 Q2 2019 Q3

Recurring Revenues Equipement Sales

› Gradual restart of sales invoicing of EOS© systems

€2.6m

€3.4m

€6.3m

39

EOS imaging | 9-months Revenues 2019 Key Facts

Conclusion & Perspectives

› Reinforcing business dynamic along 2019 with €18.6m Equipment Orders booked over 2019 YTD

• +5.9% growth over Q3 2019 compare to 2018

› Equipment Commercial cycle progressing as planned

• 9 EOS® systems delivered over Q3 2019; 11 over 2019 YTD

› Confident in delivering strong YOY commercial performance growth in Q4 and FY 2019

Release of FY 2019 Revenues on January 8, 2020

CONNECTING IMAGING TO CARE

Contact:

Phone: +33 (0)1 55 25 60 60

Email: investors@eos-imaging.com

www.eos-imaging.com